Heike Keilhack

USPTO Granted Patents = 32 (Patent Applications = 38)

CIPO Patents = 6 (Patent Applications = 9)

EPO Patents = 11 (Patent Applications = 27)

Average Co-Inventor Count = 3.2

ph-index = 10

Forward Citations = 354(Granted Patents)

Company Filing History:

Eisai R&d Management Co., Ltd.

patents

2 out of 310

Health Research, Inc.

patents

where one patent can have more than one assignee

Years Active: 2014-2024

Loading Chart...

32 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12168016 - Aryl-OR heteroaryl-substituted benzene compounds (2024-12-17),

2. 12168015 - Aryl-or heteroaryl-substituted benzene compounds (2024-12-17),

3. 12168014 - Method for treating cancer (2024-12-17),

4. 12162865 - Methods of treating cancer (2024-12-10),

5. 12161645 - Aryl-or heteroaryl-substituted benzene compounds (2024-12-10),

6. 11951109 - EZH2 inhibitors for treating lymphoma (2024-04-09),

7. 11642349 - Method for treating cancer (2023-05-09),

8. 11642347 - EZH2 inhibitors for treating lymphoma (2023-05-09),

9. 11370781 - Combination therapy for treating cancer (2022-06-28),

10. 11202781 - EZH2 inhibitors for treating lymphoma (2021-12-21),

11. 11052093 - Aryl-or heteroaryl-substituted benzene compounds (2021-07-06),

12. 11026949 - Combination therapy for treating cancer (2021-06-08),

13. 10946024 - Method for treating cancer (2021-03-16),

14. 10898490 - Method for treating cancer (2021-01-26),

15. 10787440 - Combination therapy for treating cancer (2020-09-29),

Title: The Innovator: Heike Keilhack - Pioneering Cancer Treatments

Introduction:

Heike Keilhack, a renowned inventor based in Belmont, MA (US), has made significant strides in the field of cancer research. With 27 patents to his name, he is a trailblazer in developing cutting-edge therapies for various forms of cancer.

Latest Patents:

Keilhack's latest patents showcase his innovative approach to cancer treatment. From EZH2 inhibitors for treating lymphoma to a specialized method for combating cancer, his work highlights his commitment to revolutionizing the field of oncology.

Career Highlights:

Having worked at prestigious companies such as Epizyme, Inc. and Eisai Research & Development Management Co., Ltd., Keilhack has honed his expertise in developing novel therapeutics. His contributions have not only advanced the scientific community but have also brought hope to countless patients battling cancer.

Collaborations:

Throughout his career, Keilhack has collaborated with esteemed professionals in the field, including Sarah Kathleen Knutson and Kevin Wayne Kuntz. Together, they have synergized their skills and knowledge to push the boundaries of cancer research and treatment.

Conclusion:

In conclusion, Heike Keilhack stands as a beacon of innovation in the realm of cancer therapy. His dedication to improving patient outcomes and his relentless pursuit of groundbreaking treatments underscore his position as a luminary in the field. As Keilhack continues to push the boundaries of scientific discovery, the impact of his work will undoubtedly resonate far into the future.

This text is generated by artificial intelligence and may not be accurate.